December - 2020

RICHARD SEMELKA, MD. CONSULTING

Our Recent Posts

Archive

Tags

New Frontiers: Mabs and mRNA. Could these work for GDD?

New Frontiers: Mabs and mRNA. Could these work for GDD?

Monoclonal antibodies (Mabs) have come to public attention as biologic drugs taken to specifically attack the COVID virus, and mRNA are the basis of the currently released vaccines for COVID in the USA: by Pfizer and Moderna. So these have come into the public dialogue as being important and life-saving against the COVID-19 virus SARS-cov-2. The obvious question, what about other diseases, can they work for them. Probably yes, for every type of disease that somehow is in th

GDD and Diet

GDD and Diet

I have written a few blogs on diet and GDD, but this is always worth revisiting and updating. First off, there are unlimited number of diets promoted. I like to stick with the obvious and basic. Essentially: * a mixture between elements in the South Beach, Mediterranean, and health-oriented Japanese diet makes sense. *Everything in moderation makes sense. *Natural food items, especially in the nut, fruit, and vegetable categories makes sense. * I am not convinced that exotic

Overlap Gadolinium Toxicities

Overlap Gadolinium Toxicities

Overlap conditions are very common in diseases, and often with autoimmune diseases. A condition I am very familiar with is actually called Overlap Syndrome, in which a patient has more than one of: Autoimmune hepatitis, Primary sclerosing cholangitis, and Primary biliary cirrhosis. Conditions can also be founded upon the specific genetic mutation, regardless of organ of origin (eg: kidney cancer, lung cancer, can be related based on the specific mutation) which then correlate

Immunogenicity and Efficacy

Immunogenicity and Efficacy

Adverse events from exposure to foreign antigens reflect a number of processes in the host. One of the most critical processes, which is rarely specifically called-out is immunogenicity. Efficacy is the effect that we want to see in a drug/pharmaceutical agent, and it is often confused that high immunogenicity reflects poor efficacy. They are actually distinct processes. Immunogenicity is often terms thought of in negative terms (negative immunogenicity) such as anaphylactic

Chelation Therapy for GDD. Review of Effects and New Insights

Chelation Therapy for GDD. Review of Effects and New Insights

Questions about different effects come up frequently from individuals. Hence it is worth repeating the account and adding new insights. Redistribution vs Re-equilibration Redistribution is the effect that occurs when a poor chelator for Gd is used, the poorer the chelator, the more redistribution. This effect is explained on the pure in vitro lab science of stability constant (thermodynamic stability) the more stable, the less redistribution. Stability: DTPA>>>EDTA>>DMSA, DM

The Nuances of Treatment

The Nuances of Treatment

The below is an email recently sent to an individual undergoing DTPA and immune dampening treatment. This refers to their specific set of characteristics, but one can readily introduce your own set of individual characteristics in the narrative. This emphasizes that treatment is nuanced, and unfortunately in some individuals their characteristics makes treatment a balancing act: that you are attempting to walk on the thin edge of a razor, but one which is serpiginous. As fol